Literature DB >> 26331225

Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response.

Giuseppe Murdaca1, Rodolfo Russo1, Francesca Spanò1, Diego Ferone2, Manuela Albertelli2, Angelo Schenone3, Miriam Contatore1, Andrea Guastalla1, Annamaria De Bellis4, Giacomo Garibotto1, Francesco Puppo1.   

Abstract

Diabetes insipidus is a disease in which large volumes of dilute urine (polyuria) are excreted due to vasopressin (AVP) deficiency [central diabetes insipidus (CDI)] or to AVP resistance (nephrogenic diabetes insipidus). In the majority of patients, the occurrence of CDI is related to the destruction or degeneration of neurons of the hypothalamic supraoptic and paraventricular nuclei. The most common and well recognized causes include local inflammatory or autoimmune diseases, vascular disorders, Langerhans cell histiocytosis (LCH), sarcoidosis, tumors such as germinoma/craniopharyngioma or metastases, traumatic brain injuries, intracranial surgery, and midline cerebral and cranial malformations. Here we have the opportunity to describe an unusual case of female patient who developed autoimmune CDI following ureaplasma urealyticum infection and to review the literature on this uncommon feature. Moreover, we also discussed the potential mechanisms by which ureaplasma urealyticum might favor the development of autoimmune CDI.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26331225     DOI: 10.1590/2359-3997000000072

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  2 in total

1.  Causes and Follow-Up of Central Diabetes Insipidus in Children.

Authors:  Wendong Liu; Jing Hou; Xiuqin Liu; Limin Wang; Guimei Li
Journal:  Int J Endocrinol       Date:  2019-03-27       Impact factor: 3.257

Review 2.  [Clinical implications of the genus Mycoplasma].

Authors:  D Gómez Rufo; E García Sánchez; J E García Sánchez; M García Moro
Journal:  Rev Esp Quimioter       Date:  2021-03-18       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.